Please wait a minute...
Journal of Neurorestoratology  2020, Vol. 8 Issue (4): 241-251    doi: 10.26599/JNR.2020.9040026
Special Report     
Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version)
Xiaoling Guo1,(✉)(),Qun  Xue2,(✉)(),Jianhua Zhao3,Yi Yang4,Yang Yu5,Dezhong Liu6,Jing Liu7,Wenwu Yang8,Linsen Mu9,Ping Zhang10,Tianyi Wang11,Hongyan Han12,Shoufeng Liu5,Yuhua Zhu2,Tao Wang14,Chuanqiang Qu15,On behalf of Chinese Association of Neurorestoratology (Preparatory) and China Committee of International Association of Neurorestoratology
1 Department of Neurology, 981 Hospital of PLA Joint Support Force, Chengde 067000, Hebei, China
2 Department of Neurology, First Affiliated Hospital of Suzhou University, Suzhou 215006, Jiangsu, China
3 Department of Neurology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, Henan, China
4 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
5 Department of Rehabilitation Medicine, Tianjin Huanhu Hospital, Tianjin 300350, China
6 Department of Neurosurgery, Zhoukou Central Hospital, Zhoukou 466000, Henan, China
7 Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian 116021, Liaoning, China
8 Department of Neurosurgery, 981 Hospital of PLA Joint Support Force, Chengde 067000, Hebei, China
9 Department of Neurosurgery, Guangdong 999 Brain Hospital, Guangzhou 510510, Guangdong, China
10 Department of Neurology, Shenzhen University General Hospital, Shenzhen 518055, Guangdong, China
11 Department of Orthopedics, 981 Hospital of PLA Joint Support Force, Chengde 067000, Hebei, China
12 Department of Neurosurgery, Beijing Aviation General Hospital, Beijing 100020, China
13 Department of Neurological Rehabilitation, Tianjin Huanhu Hospital, Tianjin 300350, China
14 Department of Neurosurgery, Peking University Third Hospital, Beijing 100191, China
15 Department of Neurology, Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan 250021, Shandong, China
Download: PDF (450 KB)      HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Stroke is the main cause of death and disability among Chinese, and neurorestoration is an effective therapeutic strategy for patients with stroke. In recent years, many achievements have been made in stroke neurorestoration, but viewpoints for managing stroke vary per discipline. In order to promote standardization of diagnosis and treatment for stroke neurorestoration, the Chinese Association of Neurorestoratology (CANR; Preparatory) and China Committee of International Association of Neurorestoratology (IANR-China Committee) organized professional experts in the field to integrate fragmented neurorestorative methods and establish clinical diagnostic and therapeutic guidelines for stroke neurorestoration. This guideline includes the diagnosis and staging of stroke and therapeutic recommendations for neurorestoration at different stages of stroke in order to improve survival and quality of life of stroke patients.



Key wordsneurorestoration      clinical guideline      stroke     
Received: 22 October 2020      Published: 07 February 2021
Corresponding Authors: Xiaoling Guo,Qun Xue     E-mail: gxl266@sina.com;qxue_sz@163.com
Cite this article:

Xiaoling Guo, Qun Xue, Jianhua Zhao, Yi Yang, Yang Yu, Dezhong Liu, Jing Liu, Wenwu Yang, Linsen Mu, Ping Zhang, Tianyi Wang, Hongyan Han, Shoufeng Liu, Yuhua Zhu, Tao Wang, Chuanqiang Qu. Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version). Journal of Neurorestoratology, 2020, 8: 241-251.

URL:

http://jnr.tsinghuajournals.com/10.26599/JNR.2020.9040026     OR     http://jnr.tsinghuajournals.com/Y2020/V8/I4/241

[1]   Wang WZ, Jiang B, Sun HX, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480?687 adults. Circulation. 2017, 135(8): 759-771.
[2]   Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019, 394(10204): 1145-1158.
[3]   Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993, 24(1): 35-41.
[4]   Ornello R, Degan D, Tiseo C, et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes: a systematic review and meta-analysis. Stroke. 2018, 49(4): 814-819.
[5]   Huang H, Raisman G, Sanberg PR, et al. Neurorestoratology. New York: Nova Biomedical, 2015.
[6]   Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet. 2015, 385(9967): 529-538.
[7]   Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018, 378(8): 708-718.
[8]   Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018, 378(1): 11-21.
[9]   Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014, 45(7): 2160-2236.
[10]   Moore WS, Kempczinski RF, Nelson JJ, et al. Recurrent carotid stenosis: results of the asymptomatic carotid atherosclerosis study. Stroke. 1998, 29(10): 2018-2025.
[11]   Liapis CD, Bell PR, Mikhailidis D, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg. 2009, 37(4 ): 1-19.
[12]   Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery Stenosis. N Engl J Med. 2016, 374(11): 1021-1031.
[13]   Brott TG, Calvet D, Howard G, et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data. Lancet Neurol. 2019, 18(4): 348-356.
[14]   Bonati LH, Gregson J, Dobson J, et al. Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. Lancet Neurol. 2018, 17(7): 587-596.
[15]   Chinese Society of Neurology, Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. Chin J Neurol. 2018, 51(9): 666-682.
[16]   Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2019, 50(12): e344-e418.
[17]   FDA expands treatment window for use of clot retrieval devices in certain stroke patients. (accessed 1 Oct, 2020).
[18]   Mendon?a ML, Freitas GR, Silva SA, et al. Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Arq Bras Cardiol. 2006, 86(1): 52-55.
[19]   Savitz SI, Misra V, Kasam M, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011, 70(1): 59-69.
[20]   Vahidy FS, Haque ME, Rahbar MH, et al. Intravenous bone marrow mononuclear cells for acute ischemic stroke: safety, feasibility, and effect size from a phase I clinical trial. Stem Cells. 2019, 37(11): 1481-1491.
[21]   Banerjee S, Bentley P, Hamady M, et al. Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Transl Med. 2014, 3(11): 1322-1330.
[22]   Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017, 16(5): 360-368.
[23]   McCourt R, Gould B, Gioia L, et al. Cerebral perfusion and blood pressure do not affect perihematoma edema growth in acute intracerebral hemorrhage. Stroke. 2014, 45(5): 1292-1298.
[24]   Zheng J, Li H, Lin S, et al. Perioperative antihypertensive treatment in patients with spontaneous intracerebral hemorrhage. Stroke. 2017, 48(1): 216-218.
[25]   Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/ American stroke association. Stroke. 2015, 46(7): 2032-2060.
[26]   Kim BJ, Kwon SU, Park JH, et al. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke. 2020, 51(3): 931-937.
[27]   You C, Li H. Pay more attention to and standardize the surgical treatment of hypertensive cerebral hemorrhage. Chin J Neurosurg. 2011, 27(8): 757-758.
[28]   Wang JY, Shao B, DaLin, et al. Ideal cardiovascular health metrics associated with reductions in the risk of extracranial carotid artery stenosis: a population-based cohort study. Sci Rep. 2018, 8(1): 12277.
[29]   Guay J, Kopp S. Cerebral monitors versus regional anesthesia to detect cerebral ischemia in patients undergoing carotid endarterectomy: a meta-analysis. J Can D'anesthesie. 2013, 60(3): 266-279.
[30]   Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012, 43(8): 2242-2244.
[31]   Bhatia V, Gupta V, Khurana D, et al. Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR Am J Neuroradiol. 2018, 39(5): 899-904.
[32]   Prasad K, Mohanty S, Bhatia R, et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012, 136(2): 221-228.
[33]   Taguchi A, Sakai C, Soma T, et al. Intravenous autologous bone marrow mononuclear cell transplantation for stroke: Phase1/2a clinical trial in a homogeneous group of stroke patients. Stem Cells Dev. 2015, 24(19): 2207-2218.
[34]   Bang OY, Lee JS, Lee PH, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005, 57(6): 874-882.
[35]   Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010, 28(6): 1099-1106.
[36]   Fang J, Guo Y, Tan S, et al. Autologous endothelial progenitor cells transplantation for acute ischemic stroke: a 4-year follow-up study. Stem Cells Transl Med. 2019, 8(1): 14-21.
[37]   Prasad K, Sharma A, Garg A, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014, 45(12): 3618-3624.
[38]   Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011, 6(1): 45-52.
[39]   Hammadi AMA, Alhimyari F. Intra-arterial injection of autologous bone marrow-derived mononuclear cells in ischemic stroke patients. Exp Clin Transplant. 2019, 17(): 239-241.
[40]   Bhasin A, Srivastava M, Bhatia R, et al. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med. 2012, 8(3): 181-189.
[41]   Bhasin A, Srivastava MV, Mohanty S, et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013, 115(7): 1003-1008.
[42]   Bhasin A, Srivastava MVP, Mohanty S, et al. Paracrine mechanisms of intravenous bone marrow-derived mononuclear stem cells in chronic ischemic stroke. Cerebrovasc Dis Extra. 2016, 6(3): 107-119.
[43]   Sharma A, Sane H, Gokulchandran N, et al. Autologous bone marrow mononuclear cells intrathecal transplantation in chronic stroke. Stroke Res Treat. 2014, 2014: 234095.
[44]   Chernykh ER, Shevela EY, Starostina NM, et al. Safety and therapeutic potential of M2 macrophages in stroke treatment. Cell Transplant. 2016, 25(8): 1461-1471.
[45]   Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011, 134(Pt 6): 1790-1807.
[46]   Bhasin A, Srivastava MV, Kumaran SS, et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 2011, 1(1): 93-104.
[47]   Jiang YJ, Zhu WS, Zhu JH, et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013, 22(12): 2291-2298.
[48]   Guo XL, Wang X, Li Y, et al. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review. J Neurorestoratology. 2019, 7(2): 82-88.
[49]   Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry. 2020, 91(4): 396-401.
[50]   Zhang GZ, Li Y, Reuss JL, et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke. Stem Cells Transl Med. 2019, 8(10): 999-1007.
[51]   Savitz SI, Yavagal D, Rappard G, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-stroke). Circulation. 2019, 139(2): 192-205.
[52]   Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2 double-blind, randomized, controlled trial. J Neurorestoratology. 2020, 8(3): 182-193.
[53]   Sharma A, Sane H, Nagrajan A, et al. Autologous bone marrow mononuclear cells in ischemic cerebrovascular accident paves way for neurorestoration: a case report. Case Rep Med. 2014, 2014: 530239.
[54]   Tsang KS, Ng CPS, Zhu XL, et al. Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cells. 2017, 9(8): 133-143.
[55]   Levy ML, Crawford JR, Dib N, et al. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 2019, 50(10): 2835-2841.
[56]   Al Fauzi A, Sumorejo P, Suroto NS, et al. Clinical outcomes of repeated intraventricular transplantation of autologous bone marrow mesenchymal stem cells in chronic haemorrhagic stroke. A one-year follow up. Open Neurol J. 2017, 11: 74-83.
[57]   Wang LM, Ji HJ, Li M, et al. Intrathecal administration of autologous CD34 positive cells in patients with past cerebral infarction: a safety study. ISRN Neurol. 2013, 2013: 128591.
[58]   Chen DC, Lin SZ, Fan JR, et al. Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: a randomized phase II study. Cell Transplant. 2014, 23(12): 1599-1612.
[59]   Sung PH, Lin HS, Lin WC, et al. Intra-carotid arterial transfusion of autologous circulatory derived CD34+ cells for old ischemic stroke patients - a phase I clinical trial to evaluate safety and tolerability. Am J Transl Res. 2018, 10(9): 2975-2989.
[60]   Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke. 2016, 47(7): 1817-1824.
[61]   Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2019, 131: 1462-1472.
[62]   Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016, 388(10046): 787-796.
[63]   Rabinovich SS, Seledtsov VI, Banul NV, et al. Cell therapy of brain stroke. Bull Exp Biol Med. 2005, 139(1): 126-128.
[64]   Chen L, Xi HT, Huang HY, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013, 22(): S83-S91.
[65]   Qiao LY, Huang FJ, Zhao MS, et al. A two-year follow-up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant. 2014, 23(): S65-S72.
[66]   Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005, 103(1): 38-45.
[67]   SanBio Co. Ltd. SanBio and Sumitomo Dainippon Pharma announce topline results from a phase 2b study in the U.S. evaluating SB623, a regenerative cell medicine for the treatment of patients with chronic stroke. (accessed 1 Oct, 2020).
[1] Xiaodong Guo,Yaping Feng,Tiansheng Sun,Shiqing Feng,Jiaguang Tang,Lin Chen,Xiaojian Cao,Haodong Lin,Xijing He,Meihua Li,Zhicheng Zhang,Guoyong Yin,Xifan Mei,Hongyun Huang. Clinical guidelines for neurorestorative therapies in spinal cord injury (2021 China version)[J]. Journal of Neurorestoratology, 2021, 9(1): 31-49.
[2] Yusheng Li,Jianghong He,Bo Yang,Hui Zhang,Zhonghua Yang,Jianhui Fu,Lian Huang,Hong Chen,Xiaofeng Yang,Yijun Bao. Clinical diagnosis guidelines and neurorestorative treatment for chronic disorders of consciousness (2021 China version)[J]. Journal of Neurorestoratology, 2021, 9(1): 50-59.
[3] Hongyun Huang,Wenyong Gao,Zhenghui Yan,Aibing Liu,Xijing He,Ming Lu,Ying Liu,Yixin Shen,Jianhua Zhao,Zuncheng Zheng,Tiansheng Sun,Yaojian Rao. Standards of clinical-grade olfactory ensheathing cell culture and quality control (2020 China Version)[J]. Journal of Neurorestoratology, 2020, 8(4): 217-231.
[4] Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Ying Liu, Wenyong Gao, Juan Xiao, Yanqiu Liu, Yan Li, Manli Tang, Linlin Wang, Lin Chen, Di Chen, Deqiang Guo, Fei Liu, Weidong Chen, Baomin Chan, Bo Zhou, Aibing Liu, Gengsheng Mao, Hongyun Huang. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2, double-blind, randomized, controlled trial[J]. Journal of Neurorestoratology, 2020, 8(3): 182-193.
[5] Hongyun Huang, Lin Chen, Gengsheng Mao, Hari Shanker Sharma. Clinical neurorestorative cell therapies: Developmental process, current state and future prospective[J]. Journal of Neurorestoratology, 2020, 8(2): 61-82.
[6] Miaomiao Zhuang, Qingheng Wu, Feng Wan, Yong Hu. State-of-the-art non-invasive brain–computer interface for neural rehabilitation: A review[J]. Journal of Neurorestoratology, 2020, 8(1): 12-25.
[7] Weiwei Zhao,Chuanguang Ju,Daozhen Wang,Huifen Shen. Clinical observation of effects of ultrashort wave therapy combined with acupuncture and rehabilitation training in the treatment of patients with dysphagia after stroke[J]. Journal of Neurorestoratology, 2019, 7(3): 136-142.
[8] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[9] Shina Gu, Xiaodan Li, Lin Zhao, Huicong Ren, Chendi Pei, Wenqiang Li, Junlin Mu, Jinggui Song, Zhaohui Zhang. Decreased Npas4 expression in patients with post-stroke depression[J]. Journal of Neurorestoratology, 2019, 7(2): 101-108.
[10] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[11] Zhongju Shi, Zhijian Wei, Shiqing Feng, Gustavo Moviglia, Lin Chen, Ping Wu. Highlights for the 10th Annual Conference of the International Association of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 84-87.
[12] Lin Chen, Yuqi Zhang, Xijing He, Saberi Hooshang. Comparison of intramedullary transplantation of olfactory ensheathing cell for patients with chronic complete spinal cord injury worldwide[J]. Journal of Neurorestoratology, 2018, 6(1): 146-151.
[13] Feng Zhang, Xiangzhi Meng, Fang Lu, Aixian Liu, Hongyun Huang. Olfactory ensheathing cell transplantation for a patient with chronic sciatic nerve injury[J]. Journal of Neurorestoratology, 2017, 5(1): 1-4.
[14] Hongyun Huang, Lin Chen, Qingyan Zou, Fabin Han, Tiansheng Sun, Gengsheng Mao, Xijing He. Clinical cell therapy guidelines for neurorestoration (China version 2016)[J]. Journal of Neurorestoratology, 2017, 5(1): 39-46.
[15] Ye Zhang, Hong Deng, Chao Pan, Yang Hu, Qian Wu, Na Liu, Zhouping Tang. Mesenchymal stromal cell therapy in ischemic stroke[J]. Journal of Neurorestoratology, 2016, 4(1): 79-84.